Steatohepatitis/Metabolic Liver Disease News

Hispanic adults in the U.S. who have high levels of some liver enzymes have an increased risk for developing diabetes, according to a study published in Diabetic Medicine.

Patients with non-alcoholic fatty liver disease who underwent endoscopic bariatric and metabolic therapies saw improvements in liver fibrosis and other outcomes, according to study results.

Patients with non-alcoholic fatty liver disease had a moderately increased risk for extrahepatic cancers, such as gastrointestinal, breast and gynecological cancers, according to a meta-analysis.

Exposure to passive smoking from childhood through adulthood was associated with increased risk for non-alcoholic fatty liver disease, according to study results.

The AGA Institute Clinical Practice Updates Committee and the Governing Board published evidence-based intervention advice for lifestyle modifications for treating nonalcoholic fatty liver disease in Gastroenterology.

Metabolic dysfunction-associated fatty liver disease is highly prevalent among overweight and obese adults, according to Clinical Gastroenterology and Hepatology.

Healio Gastroenterology spoke with Wayne Eskridge, founder and CEO of the Fatty Liver Foundation on the goals the foundation has this year, including increasing screening for liver disease and working around the COVID-19 pandemic.

During a follow-up of 39 months, 32% of overweight or obese patients with nonalcoholic fatty liver disease achieved 5% or greater weight loss, according to results published in Clinical Gastroenterology and Hepatology.

In this exclusive video, Eric Lawitz, MD, from the Texas Liver Institute, University of Texas Health, San Antonio, spoke about DUR-928, a daily oral treatment for nonalcoholic steatohepatitis.

A Mediterranean diet combined with green plant-based proteins/polyphenols and restricted in red/processed meat may double intrahepatic fat loss and reduce non-alcoholic fatty liver disease by half, according to study results.